Genmab Names Séverine Lemoine as France GM

Key highlights
  • Séverine Lemoine appointed as General Manager for France.
  • Genmab focuses on expanding its presence in Europe.
  • Lemoine has over 20 years of oncology leadership experience.
  • Genmab specializes in antibody-based science.

Appointment Announcement

Séverine Lemoine has been appointed as the General Manager for France by Genmab. This move is part of Genmab's strategy to expand its operations in Europe and enhance its presence in the French market.

Role and Responsibilities

In her new role, Lemoine will oversee Genmab's operations in France. Her responsibilities include building the company's local footprint, driving the success of future product launches, and contributing to the local life sciences ecosystem.

Professional Background

Lemoine brings over 20 years of leadership experience in oncology, having held senior positions at companies like Moderna, Seagen, Roche, Novartis, and AstraZeneca. Her expertise includes building business operations and launching oncology medicines, particularly in women's cancers.

Educational Qualifications

Séverine Lemoine holds a Doctor of Pharmacy degree from Université René Descartes – Paris V and a Master’s in Marketing Management from the ESSEC Healthcare Chair at ESSEC Business School.

Source: Genmab

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time.

Related articles

26 February 2026
BASF Appoints Thomas Biegi for Communications and Government Relations

Thomas Biegi, with a strong background in pharma and biotech communications, will succeed Nina Schwab-Hautzinger in April 2026, reporting to Markus Kamieth.

17 February 2026
Genmab Releases 2025 Annual Report

The report highlights 2025 achievements, financials, and 2026 outlook, including revenue growth, strategic acquisitions, and regulatory approvals.

6 November 2025
Genmab Reports Q3 2025 Financial Results

Revenue up 21% to $2.66B. Proposed Merus acquisition. FDA priority review for epcoritamab. Rina-S gets Breakthrough Therapy Designation. Operating profit rose to $1.007B.

24 July 2026
Roche’s Susvimo recommended by CHMP for nAMD

First continuous‑delivery ranibizumab implant for nAMD receives CHMP backing; designed to maintain vision with as few as two refills per year versus monthly injections.

29 April 2026
Genentech to present ophthalmology data at ARVO 2026

ARVO presentations: real-world Vabysmo data show retinal drying in wet AMD/DME; Susvimo demonstrates sustained delivery and reduced treatment burden; vamikibart shows early efficacy; >45 abstracts